OVID
MaterialsOvid Therapeutics Inc
$2.78-0.05 (-1.77%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OVID Today?
No stock-specific AI insight has been generated for OVID yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$481M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding173.0M
OVID News
20 articles- Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14Yahoo Finance·Apr 8, 2026
- Ovid Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 18, 2026
- Here's Why Ovid Therapeutics Stock Popped Higher TodayMotley Fool·Mar 18, 2026
- Exchange-Traded Funds, Equity Futures Lower Ahead of Key Economic Data, FOMC MeetingYahoo Finance·Mar 18, 2026
- Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass EstimatesYahoo Finance·Mar 18, 2026
- Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 18, 2026
- Ovid Therapeutics Announces Pricing of $60 Million Private PlacementYahoo Finance·Mar 18, 2026
- Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 4, 2026
- Ovid Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Feb 20, 2026
- Ovid takes another big swing in neuroscience under a new CEOPharmavoice·Feb 13, 2026
- Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?Yahoo Finance·Jan 30, 2026
- Promising Penny Stocks To Watch In December 2025Yahoo Finance·Dec 26, 2025
- Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)Yahoo Finance·Dec 18, 2025
- Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical OfficerYahoo Finance·Dec 2, 2025
- November 2025's Top Penny Stock OpportunitiesYahoo Finance·Nov 27, 2025
- Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 12, 2025
- Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial ResultsYahoo Finance·Nov 12, 2025
- Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer dataBiopharmadive·Nov 12, 2025
- QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical OfficerYahoo Finance·Nov 10, 2025
All 20 articles loaded
Price Data
Open$2.83
Previous Close$2.83
Day High$2.95
Day Low$2.75
52 Week High—
52 Week Low—
Fundamentals
Market Cap$481M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding173.0M
About Ovid Therapeutics Inc
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—